| Bioactivity | Thalidomide-O-C6-azide is a synthesized E3 ligase ligand-linker conjugate (E3 Ligase Ligand-Linker Conjugates) that incorporates the Thalidomide (Thalidomide (HY-14658)) based cereblon ligand and a linker used in PROTAC technology[1]. |
| Invitro | PROTAC 包含两个不同的配体，通过一个接头连接；一个是 E3 泛素连接酶的配体，另一个是靶蛋白的配体。 PROTAC 利用细胞内泛素-蛋白酶体系统选择性降解靶蛋白[2]。 |
| Name | Thalidomide-O-C6-azide |
| CAS | 2411389-65-4 |
| Formula | C19H21N5O5 |
| Molar Mass | 399.40 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | -20°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
| Reference | [1]. Chen P, et al. α-naphthoflavone-derived cytochrome P450 (CYP)1B1 degraders specific for sensitizing CYP1B1-mediated drug resistance to prostate cancer DU145: Structure activity relationship. Bioorg Chem. 2021 Nov;116:105295. [2]. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-996. |
Thalidomide-O-C6-azide
CAS: 2411389-65-4 F: C19H21N5O5 W: 399.40
Thalidomide-O-C6-azide is a synthesized E3 ligase ligand-linker conjugate (E3 Ligase Ligand-Linker Conjugates) that inco
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.